Ratio Therapeutics
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer.Ratio Therapeutics’ TrilliumTM targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
Ratio Therapeutics is a biotechnology research company headquartered in Boston, Massachusetts, United States. The team counts 84 people, up 24% over the last year. Ratio Therapeutics has 1 open role right now and a website drawing 4K monthly visits.
Employee growth
Ratio Therapeutics grew from ~15 employees in June 2022 to 43 by July 2024, reaching 84 by August 2026, tracked weekly in Crustdata's proprietary dataset since June 2022.
Capital raised
Ratio Therapeutics has raised $160M across 4 rounds since 2022 - from a $20M Series A to a $70M Series C - most recently 18 days ago.
-
In July 2026, Ratio Therapeutics raised $70M in a Series C round.
-
In January 2024, Ratio Therapeutics raised $50M in a Series B round.
-
In February 2023, Ratio Therapeutics raised $20M in a Series A round.
-
In June 2022, Ratio Therapeutics raised $20M in a Seed Round round.
Investors
Ratio Therapeutics's 5 backers include leading firms such as The Pags Group, Bristol-Myers Squibb, Duquesne Capital Management, and Cornell University.
Leadership
Ratio Therapeutics's leadership includes Chief Medical Officer Colin Hayward, Chief Business Officer Bill Cupelo, Chief Strategy Officer Marcel R., and President & Chief Scientific Officer John Babich.
Industries & markets
Ratio Therapeutics is classified across the following industries, categories, and markets that Crustdata tracks for competitive analysis and sector benchmarking.
See the top Biotechnology Research companies ranked by size, growth and funding.
In the news
Ratio Therapeutics has been featured in recent press coverage that Crustdata tracks to surface signals on launches, fundraising, partnerships, and other newsworthy events.
- Ratio Therapeutics Closes $70 Million Series C Financing to Advance Clinical Development of Targeted Radiotherapeutics Pipeline and Expand Manufacturing Infrastructure
- Ratio Therapeutics Secures $70 Million Series C Financing To Advance Clinical Development Of Targeted Radiotherapeutics Pipeline
- /C O R R E C T I O N -- Ratio Therapeutics Inc./
- Ratio Therapeutics Enters Strategic Actinium-225 Supply Agreement with PanTera to Support Radiopharmaceutical Development Programs
Open positions
Ratio Therapeutics has 1 open role, 100% based in the US.
Ratio Therapeutics is hiring for 1 role in United States.
Ratio Therapeutics Growth Score
Ratio Therapeutics has a Crustdata Growth Score of 63 out of 100, which points to strong growth. Behind the number: headcount grew 24% year over year, web traffic grew 87% quarter over quarter, 1 role is open, and it last raised funding 1 month ago.
Ratio Therapeutics FAQs
Below are 11 of the most common questions about Ratio Therapeutics, answered with data tracked and refreshed weekly using Crustdata's proprietary dataset.